Cost-effectiveness (CE) of regorafenib dose optimization schedule in metastatic colorectal cancer. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not include ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results